210 related articles for article (PubMed ID: 35712122)
1. Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect.
Prasit KK; Ferrer-Font L; Burn OK; Anderson RJ; Compton BJ; Schmidt AJ; Mayer JU; Chen CJ; Dasyam N; Ritchie DS; Godfrey DI; Mattarollo SR; Dundar PR; Painter GF; Hermans IF
Oncoimmunology; 2022; 11(1):2081009. PubMed ID: 35712122
[TBL] [Abstract][Full Text] [Related]
2. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
[TBL] [Abstract][Full Text] [Related]
3. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
4. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
5. H2-D(d)-mediated upregulation of interleukin-4 production by natural killer T-cell and dendritic cell interaction.
Mizuuchi K; Yanagawa Y; Iwabuchi K; Namba K; Kitaichi N; Ohno S; Onoé K
Immunology; 2008 May; 124(1):102-11. PubMed ID: 18194275
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
7. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
8. Temporal Regulation of Natural Killer T Cell Interferon Gamma Responses by β-Catenin-Dependent and -Independent Wnt Signaling.
Kling JC; Jordan MA; Pitt LA; Meiners J; Thanh-Tran T; Tran LS; Nguyen TTK; Mittal D; Villani R; Steptoe RJ; Khosrotehrani K; Berzins SP; Baxter AG; Godfrey DI; Blumenthal A
Front Immunol; 2018; 9():483. PubMed ID: 29616022
[TBL] [Abstract][Full Text] [Related]
9. Exposure of polyethylene particles induces interferon-γ expression in a natural killer T lymphocyte and dendritic cell coculture system in vitro: a preliminary study.
Lin TH; Kao S; Sato T; Pajarinen J; Zhang R; Loi F; Goodman SB; Yao Z
J Biomed Mater Res A; 2015 Jan; 103(1):71-5. PubMed ID: 24616165
[TBL] [Abstract][Full Text] [Related]
10. IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells.
Maeda M; Yanagawa Y; Iwabuchi K; Minami K; Nakamaru Y; Takagi D; Fukuda S; Onoé K
Immunobiology; 2007; 212(7):537-47. PubMed ID: 17678711
[TBL] [Abstract][Full Text] [Related]
11. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
12. Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice.
Zhang J; Bi J; Ren Y; Du Z; Li T; Li Q; Ke M; Dong J; Lv Y; Wu R
Cytokine; 2018 Nov; 111():237-245. PubMed ID: 30195979
[TBL] [Abstract][Full Text] [Related]
13. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile.
Gustafsson K; Junevik K; Werlenius O; Holmgren S; Karlsson-Parra A; Andersson PO
Scand J Immunol; 2011 Sep; 74(3):318-326. PubMed ID: 21595737
[TBL] [Abstract][Full Text] [Related]
14. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
[TBL] [Abstract][Full Text] [Related]
15. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
16. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes.
Chen YG; Choisy-Rossi CM; Holl TM; Chapman HD; Besra GS; Porcelli SA; Shaffer DJ; Roopenian D; Wilson SB; Serreze DV
J Immunol; 2005 Feb; 174(3):1196-204. PubMed ID: 15661873
[TBL] [Abstract][Full Text] [Related]
17. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution models to evaluate natural killer T cell function in tumor control.
Gebremeskel S; Slauenwhite D; Johnston B
Immunol Cell Biol; 2016 Jan; 94(1):90-100. PubMed ID: 26095148
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF
PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862
[TBL] [Abstract][Full Text] [Related]
20. The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma.
Zhou Z; Lin L; An Y; Zhan M; Chen Y; Cai M; Zhu X; Lu L; Zhu K
J Hepatocell Carcinoma; 2021; 8():529-543. PubMed ID: 34136421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
